Atlas Trials

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Clinical trial NCT01599949 · COMPLETED

Trial details

NCT number
NCT01599949
Sponsor
Janssen Research & Development, LLC
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Mantle Cell Lymphoma
Start date
2012-08-01
Primary completion
2015-05-01
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.